Thymosin Beta-4
Aliases: Tβ4 · TMSB4X
Last verified: 2026-09-23
The short version
A natural 43-amino-acid peptide present in all cells; the parent peptide of TB-500. Investigated for wound healing, heart and eye indications. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Phase I/II trials in epidermolysis bullosa, dry eye and cardiac ischemia; regenerative properties confirmed across preclinical models. Status: in clinical trials. Not approved; in clinical development. WADA-banned.
Identity & type
- Molecular type
- peptide
- Origin
- A natural 43-amino-acid peptide present in all cells; the parent peptide of TB-500.
Mechanism of action
Major intracellular regulator of actin polymerization; promotes cell migration, reduces apoptosis and fibrosis, modulates inflammation.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Thymosin Beta-4. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
No established human regimen; topical in wound trials; experimentally 2–10 mg SC weekly. As the natural form of TB-500 — the community uses the TB-500 fragment for cost reasons; effects overlap: recovery, reduced inflammation, cardiac protection after infarction in some (investigational).
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
As the natural form of TB-500 — the community uses the TB-500 fragment for cost reasons; effects overlap: recovery, reduced inflammation, cardiac protection after infarction in some (investigational).
Protocol — official vs community
Official / label
No approved injectable protocol. Endogenous TB-4 is studied in cardiac repair and dermal healing trials.
Duration: Study use only.
The human data belongs to specific wound/cardiological contexts, not athletic recovery.
Community (anecdotal)
Where used, mirrors TB-500 (TB-500 is itself a fragment of TB-4).
- Cycle:
- 4–8 weeks.
- Break:
- 2–4 weeks.
Most 'TB-4' vials are functionally TB-500; the nomenclature is marketing as much as chemistry.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Phase I/II trials in epidermolysis bullosa, dry eye and cardiac ischemia; regenerative properties confirmed across preclinical models.
Preclinical evidence
Phase I/II trials in epidermolysis bullosa, dry eye and cardiac ischemia; regenerative properties confirmed across preclinical models.
Known risks
- Well tolerated in limited trials; possible local reactions.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.